EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Chiara Molinelli, Marco Bruzzone, Eva Blondeaux, Tommaso Ruelle, Chiara Lanzavecchia, Michelino De Laurentiis, Stefania Russo, Ferdinando Riccardi, Valentina Sini, Francesco Cognetti, Grazia Arpino, Alessandra Fabi und 7 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.115113 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Chiara Molinelli und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; Department of Medical Oncolo…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Protein Kinase InhibitorsReceptors, EstrogenReceptors, ProgesteroneHumansFemaleMiddle AgedAgedRetrospective StudiesProspective StudiesAdultAntineoplastic Combined Chemotherapy ProtocolsAged, 80 and overDrug Resistance, Neoplasm

Stichwörter der Autor:innen

CDK 4/6 inhibitorsHER2-lowLuminal breast cancerMetastatic breast cancerSecond-line treatment

Substanzen

Erb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4Protein Kinase InhibitorsReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, humanCDK6 protein, humanCDK4 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Ma…
  • U. O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.
  • Department of Oncology, ASU FC University Hospital, Udine, Italy.
  • U.O.C. Oncologia, AORN Cardarelli, Napoli, Italy.
  • UOSD Centro Oncologico S. Spirito e Nuovo Regina Margherita, ASL Roma 1, Rome, Italy.

Zitieren

APA

Molinelli, C., Bruzzone, M., Blondeaux, E., Ruelle, T., Lanzavecchia, C., De Laurentiis, M., Russo, S., Riccardi, F., Sini, V., Cognetti, F., Arpino, G., Fabi, A., Pugliese, P., Collovà, E., Fontana, A., Puglisi, F., Bighin, C., Lambertini, M., & Del Mastro, L. (2024). The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115113

Vancouver

Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, et al. The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.115113

BibTeX
@article{Molinelli2024,
  author = {Molinelli, Chiara and Bruzzone, Marco and Blondeaux, Eva and Ruelle, Tommaso and Lanzavecchia, Chiara and De Laurentiis, Michelino and Russo, Stefania and Riccardi, Ferdinando and Sini, Valentina and Cognetti, Francesco and Arpino, Grazia and Fabi, Alessandra and Pugliese, Palma and Collovà, Elena and Fontana, Andrea and Puglisi, Fabio and Bighin, Claudia and Lambertini, Matteo and Del Mastro, Lucia},
  title = {The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.115113}
}
Kostenlos starten →